Previous 10 |
Cellular Biomedicine (NASDAQ: CBMG ): Q3 GAAP EPS of -$0.72 misses by $0.21 . More news on: Cellular Biomedicine Group, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Debuted its next 12-18 months’ immuno-oncology clinical development programs for both hematologic malignancies and solid tumors to key opinion leaders, investment and industry executives Licensed patents from the National Cancer Institute (“NCI”) to develop the next g...
SHANGHAI, China and CUPERTINO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem c...
Deals and Financings Shanghai Fosun Pharma (HK: 02196: SHA: 600196) announced it will seek a Hong Kong IPO for Shanghai Henlius Biotech, its monoclonal antibody JV subsidiary. At the same time, the company will withdraw its application for a listing on China's Third Board, the National Equit...
SHANGHAI, China and CUPERTINO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell...
Deals And Financings ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhou, will be acquired by Agilent (NYSE: A) for $250 million in cash (see story ). ACEA has developed the xCELLigence® cell therapy analysis device intended for academic and biop...
Cellular Biomedicine Group (NASDAQ: CBMG ) has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license. More news...
Collaboration with Novartis includes $40 million equity investment in CBMG for 1,458,257 shares at $27.43 /share CBMG to license select proprietary technology to Novartis for global use CBMG to manufacture and supply Kymriah® (tisagenlecleucel) in China SHANGHAI and ...
News, Short Squeeze, Breakout and More Instantly...
Cellular Biomedicine Group Inc. Company Name:
CBMG Stock Symbol:
NASDAQ Market:
Cellular Biomedicine Group Inc. Website:
Cellular Biomedicine Group, Inc. Announces Completion of Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 19, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (th...
Cellular Biomedicine Group, Inc. Stockholders Approve Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Feb. 8, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company's special meeting...
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger PR Newswire ROCKVILLE, Md. and SHANGHAI , Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company,...